AstraZeneca Treatments Win Orphan FDA Status in Liver Cancer
This article is for subscribers only.
Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.
Two AstraZeneca Plc cancer drugs received orphan status for treatment of liver cancer, a designation that may eventually speed progress to approval.